Albany Molecular Research Inc.
AMRI, a publicly traded company headquartered in Albany, works on a contract basis to help companies and scientists take promising drug therapies from the lab to the clinical-trial stage, in addition to developing its own intellectual property. The company has 1,300 employees and is best known for developing the active ingredient in the allergy medication Allegra.
AMRI has announced several partnerships to date:
- June 1, 2015 - AMRI announces collaborative, three-year agreement with HarkerBIO, a Buffalo-based start-up company, to jointly market their services to international pharmaceutical and biotech firms. Under the agreement, AMRI gains access to HarkerBIO technology that helps companies better understand the three-dimensional structures of diseases, while HarkerBIO’s customers benefit from AMRI’s global reach and its integrated drug-discovery platforms.
- June 17, 2015 - AMRI and PerkinElmer Inc. announce strategic collaboration. PerkinElmer, based in Waltham, Mass., makes instruments for environmental testing and has a human health division that makes products for screening of newborns for infectious diseases, among other equipment used in the drug-development process. In Buffalo, PerkinElmer will provide and manage equipment for AMRI and to future partners in the biotech hub.
- January 14, 2016 - AMRI announced that it signed a collaboration agreement with the New York Center for Nanomedicine Research (NYCNMR) to co-market its nanotechnology services to global pharmaceutical and biotechnology clients. As part of the three-year agreement, AMRI gains access to NYCNMR’s nanoscale therapeutic and formulation services.
AMRI occupies the seventh floor of the seven-story Conventus Building, initially moving into the space in the second quarter of 2015.
Albany Molecular Research Inc. (AMRI) conducts research in early-stage drug discovery and will be creating, along with its partners, 250 jobs in pharma-related research and development in Buffalo. This project establishes Western New York as a centerpiece of cutting edge research to drive exciting drug discoveries that advance the treatment and prevention of disease and improve the quality of life, while addressing our nation’s critical challenges in providing effective and affordable health care for an aging Baby Boomer population. A $50 million State investment in AMRI will leverage $200 million in private sector investment.